Responding to the AIDS epidemic in Angola by Williams, Brian G.
1 
Responding to the AIDS epidemic in Angola  
Brian G. Williams 
 
 South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch, South Africa 
Correspondence to BrianGerardWilliams@gmail.com 
Summary 
The epidemic of HIV in Angola started later and stabilized at lower levels than in most countries in southern Africa. Some 
studies suggest that certain high risk groups account for a substantial part of the total number of infections. With a relatively 
small population and a relatively high gross domestic product, Angola is in a good position to intervene decisively to control 
HIV. The effectiveness, availability and affordability of potent anti-retroviral therapy (ART) make it possible to contemplate 
ending the epidemic of HIV/AIDS in Angola. In this paper we consider what would have happened without ART, the No ART  
counterfactual, the impact on the epidemic if the current roll-out of ART is maintained, the ‘Current Programme’, the impact 
if coverage is rapidly increased to reach 90% of people with CD4+ cell counts below 350/μL by 2015 and HIV-positive 
pregnant women are all offered ART for life (‘Option B+’), the ‘Accelerated Programme’, and what might be possible under 
the 2013 guidelines from the World Health Organization, starting in 2015 and reaching full coverage of ART by 2018, the 
Expanded Programme. 
Current Programme 
The number of people receiving ART in Angola has doubled in the last 3 years from 20 thousand in 2009 to 42 thousand in 
2012. Compared to the No ART counter-factual the Current Programme will, by 2015, reduce the prevalence of HIV among 
adults not on ART from 2.5% to 1.8%, the annual incidence from 0.24% to 0.18%, and AIDS related deaths from 0.20% to 
0.10% p.a. By 2015 the Current Programme will have averted 24 thousand new infections in adults, 8.6 thousand new 
infections in new born children, saved 51 thousand lives, and US$51M. 
Accelerated Programme  
Under the Accelerated Programme the number of people starting treatment would have to be doubled between now and 2015. 
Compared to the Current Programme this will further reduce the prevalence among adults not on ART from 1.8% under the  to 
1.4%, the incidence from 0.18% p.a. to 0.14% p.a., and AIDS related deaths from 0.10% p.a. to 0.05%. By 2015 the 
Accelerated Programme will have averted an additional 4 thousand new infections in adults, 1.7 thousand infections in new 
born children, saved 7 thousand lives, and US$51M. 
Expanded Programme 
Under the Expanded Programme 90% of all HIV positive people will have access to immediate treatment by 2020. Compared 
to the Accelerated Programme this will further reduce the prevalence among adults not on ART in 2020 from 0.84% to 0.14%, 
incidence from 0.11% p.a. to 0.02% p.a., and AIDS deaths from 0.01% p.a. to elimination under the Expanded Programme. 
By 2020 the Accelerated Programme will have averted an additional 27 thousand new infections in adults, 6 thousand 
infections in new born children, saved an additional 4 thousand lives, and US$51M.  
 If Angola is to reach the 2015 targets in the Presidents Acceleration Plan, several key areas must be addressed. Testing 
services will need to be expanded rapidly supported by a mass testing campaign, so as to diagnose people with HIV and enrol 
them in treatment and care. A regular and uninterrupted supply of drugs will have to be assured. The quantity and quality of 
existing health staff will need to be strengthened. Community health workers will need to be mobilized and trained to 
encourage people to be tested and accept treatment, to monitor progress and to support people on treatment; this in turn will 
help to reduce stigma and discrimination, loss to follow up of people diagnosed with HIV, and improve adherence for those on 
treatment. Effective monitoring and evaluation systems will have to be in place and data collection will have to be extended 
and improved to support the development of reliable estimates of the current and future state of the epidemic, the success of 
the programme, levels of viral load suppression for those on ART and the incidence of infection. 
 If Angola succeeds in reaching the targets in the Presidents Acceleration Plan, this would provide the foundation for 
development and implementation of the Expanded Programme, ensuring that almost all HIV-positive people have access to 
ART. This will require an even greater initial commitment, political as well as financial, but should lead to the elimination of 
transmission and, eventually, the end of the pandemic. 
 
Introduction 
The prevalence of HIV infection among women attending 
ante-natal clinics (ANC) in Angola has now stabilized at a 
prevalence that is lower than in most of southern Africa. 
The Current Programme of anti-retroviral therapy (ART) 
was started in 2003 and has already reduced AIDS related 
mortality significantly. Following the current 
recommendations of the World Health Organization 
(WHO),1 the Angolan Government is considering 
expanding the provision of ART. Here we estimate the 
impact on the epidemic if 1) the Current Programme of 
ART provision is continued, 2) the Accelerated 
Programme is successfully implemented so that 90% of 
those currently in need of treatment have access to 
treatment by 2015, 3) the provision of ART is further 
expanded after 2015 in accordance with the new (2013) 
WHO guidelines for starting treatment.1 
 We start from data on the prevalence of HIV among 
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women attending ante-natal clinics in ANC facilities in the 
districts of Angola (Appendix 1). We use these data to 
estimate the year in which the HIV epidemic started and 
the asymptotic prevalence in each district. We combine 
these estimates to obtain a national estimate of the time 
trend in the prevalence of HIV. We fit the national trend in 
prevalence to a dynamical model to estimate current and to 
project future, trends in prevalence, incidence, treatment 
needs and deaths. We estimate the per capita cost of 
HIV/AIDS, including the cost of providing drugs, 
providing support to people on ART, and hospitalization 
and access to primary health care facilities for people who 
are not on ART and develop AIDS related conditions. We 
do not include the social and economic costs incurred 
when people die of AIDS so that this calculation is 
conservative with regards to the overall cost to society. 
Data 
The ANC data (Appendix 1) are sparse; in some years no 
data were collected and most facilities reported for only a 
few years. The timing of the epidemic is important: the 
earlier the epidemic started the more people are likely to 
have advanced HIV-disease and vice versa. We therefore 
consider each data set in separately and then combine them 
to arrive at an epidemic curve for the country as a whole. 
Further details are given in Appendix 1. 
 In generalized epidemics the prevalence of HIV is 
higher in pregnant women than in women in the general 
population and is higher in women than in men. The 
prevalence of infection among ANC women has therefore 
been scaled down by 20% to give the prevalence in all 
adults following UNAIDS recommendations.2  
Table 1. Annual cost of days in hospital, primary health care 
visits and counselling and testing from Granich et al.3 Costs 
are for the year 2013. The number of inpatient days and 
primary health care visits are based on data for South Africa.4 
Item Cost (US$) 
Inpatient days  not on ART  568 
Inpatient days  on ART  138 
Primary health care visits not on ART   154 
Primary health care visits  on ART   269 
Counselling and testing per test  20 
Community care and support on ART  250 
 
 Costs include hospitalization, primary health care and 
treatment.3 Drug costs are in Table 2. We do not discount 
future costs but the data presented here could be used to 
discount costs and benefits at any desired rate.  
Table 2. Annual cost of ART in South Africa. 
Year Cost (US$) 
1995  10,0005 
2003  1,7006 
2006    7307 
2009  1883 
2014  1008,9 
 
 The cost of combination ART in South Africa has 
declined dramatically since it first became available (Table 
2 and Figure 1). Since drug costs are likely to decline in 
Angola in the near future we set all drug costs to those for 
South Africa4 (red line, Figure 1). 
Epidemic Model 
The model is a standard dynamical model discussed in 
detail elsewhere.10,11 It includes uninfected people who are 
susceptible to infection while infected people go through 
four stages of infection to death to match the known 
Weibull survival for people infected with HIV but not 
ART.12 To account for heterogeneity in the risk of 
infection we let the transmission parameter decline with 
the prevalence of HIV10,11 according to a cumulative 
Weibull distribution with a shape parameter of 2.25 
(Appendix 2). 
 
 
 
 
 
 
 
 
Figure 1. Annual cost of ART per person per 
year in South Africa4 (blue dots; Table 1) fitted 
to a logistic curve (red line). Large dots give 
current prices in Angola: purple: children; 
brown: first line; green: PMTCT; red: second 
line (Appendix 4). 
Fitting the model 
We first fit the model to the prevalence data without 
including ART to get a null model against which to 
compare the impact of ART. We vary the prevalence of 
infection in 1980, which determines the timing of the 
epidemic, the rate of increase and the rate at which the risk 
of infection declines as the prevalence increases as this, in 
turn, determines the peak value of the prevalence. We also 
vary the parameter that determines the shape of the 
function relating transmission to prevalence (Appendix 2). 
The fitted values are in Table 3.  
 To model the provision of ART in the Current 
Programme we assume that certain proportions of people 
in the third and fourth stages of HIV infection start ART 
and that coverage increases logistically. We then vary the 
rate and timing of the increase and the proportion of 
people starting treatment in each stage to match the 
reported ART coverage.2 To model the Accelerated 
Programme we further increase the proportion of people 
starting treatment in WHO clinical stages 3 and 4 to 80% 
and set the rate at which this roll-out happens to 2.0/year. 
Under the Accelerated Programme 90% of all pregnant 
women are started on ART for life. To model the Extended 
Programme we include active case finding and assume 
that coverage increases logistically at a realistic rate, 
timing and asymptotic coverage. We assume that all those 
that are found to be HIV-positive, in any stage of 
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infection, are eligible for treatment. The parameter values 
are in Table 4. 
 
Table 3. The birth, background mortality and transition 
rates are fixed;10 the other parameters are varied to 
optimize the fit to the trend in the prevalence of HIV 
shown in Figure 2 (below). 
Parameter Value 
Adult population in 2013 (millions) 9.27 
Population growth rate (percent/yr) 2.2 
Background mortality (percent/yr) 1.8 
Force of infection/yr 0.726 
Prevalence at which transmission is halved (%) 1.3 
Shape parameter (see Appendix 2) 2.25 
Transition rate/yr between HIV stages off ART 0.348 
Transition rate/yr between HIV stages on ART 0.087 
 
 
Table 4. Model parameters for logistic functions. Coverage 
gives the asymptotic coverage; Rate the exponential rate of 
increase; Half-max the year when coverage reaches half the 
maximum value. OR is the odds-ratio for the number tested to 
the prevalence of HIV in that stage. 
 Parameter Value 
Coverage 0.19 
Rate per annum 1.00 
Half-max. (year) 2000.0 
 
Passive case 
finding: Stage 4 
 OR (testing) 1 
Coverage 0.10 
Rate per annum 1.00 
Half-max. (year) 2000.0 
Passive case 
Finding: Stage 3 
 
OR (testing) 2 
Coverage 0.90 
Rate per annum 2.00 
Half-max. (year) 2016.0 
Test interval (yrs) 1.00 
Active case finding: 
testing 
 
OR (testing) 10 
Coverage 0.90 
Rate per annum 2.00 
Active case finding: 
take-up 
 Half-max. (year) 2016.0 
 
Testing rates and costs 
In the model a proportion of HIV-positive people are 
tested a certain number of times each year and a 
proportion of those that test positive start ART. However, 
many people who are not infected will also be tested and 
in order to determine the cost of testing we need to know 
the case detection rate, that is the proportion of all those 
tested that are infected with HIV. Under passive case-
finding, people present to a health-service in Stages 3 or 4 
of HIV infection. We assume that all those that present in 
Stage 4 will be infected with HIV but that only 50% of 
those that present in Stage 3 will be infected with HIV. 
Under active case finding we assume that only 2% of those 
that are tested will be infected with HIV. Since we also 
have to avoid the mathematical possibility that we test 
more people than there are in the population we set the 
odds ratio for the number tested to the number that are 
HIV-positive to 1 for stage 4, 2 for stage 3, and 50 for 
active case-finding; when the prevalence is low the 
number that are positive is 100%, 50% or 2%, 
respectively, of the number tested but when the prevalence 
is high the number tested in each test interval never 
exceeds the total population. 
Results 
The fitted data and implied trends in prevalence, incidence 
and mortality as well as the number on treatment and the 
rate at which people start treatment, are shown in Figure 2 
using the parameter values in Table 3 and Table 4. Figure 
2 gives, from left to right, the prevalence of infection, the 
incidence of infection and of treatment, and the costs. 
From top to bottom the graphs give the counterfactual 
under the No ART counterfactual, the Current Programme, 
the Accelerated Programme, and the Expanded 
Programme.   
No ART 
Figure 2A gives the prevalence of HIV, Figure 2B the 
implied incidence (red line) and mortality (black line) and 
Figure 2C the implied costs of in-patient and out-patient 
care3 (red line). Prevalence rises rapidly to a steady state 
and remains fairly constant at about 2.5% after 2005. 
Incidence peaks, declines as the epidemic saturates and 
people start to die, and levels off at about 0.25% per year. 
Mortality rises about ten years after the incidence, 
reflecting the mean life-expectancy of people with HIV, 
and levels off at 0.19% per year. The annual cost to the 
health system would have increased to US$8 per adult per 
year, or US$72M per year, in 2013 and then remained 
constant. The rapid decline in incidence from 0.57% p.a. 
in 2005 to 0.22% in 2010 (Figure 2B red line) reflects the 
intrinsic dynamics of the epidemic through the saturation 
of the relatively small number of Angolan’s that are at risk 
of infection and the increasing mortality as those that are 
infected begin to die. 
Current Programme 
The provision of ART on a significant scale in the public 
sector in Angola began in about 2005. Following the then 
recommendations of the World Health Organization 
(WHO)13 infected people only started ART when their 
CD4+ cell count fell to 200/μL or they were in Clinical 
Stages 3 or 4.14 In 2006 WHO increased the CD4+ cell 
count at which people should start ART to 350/μL and the 
Angolan government followed suit. Figure 2D gives the 
HIV prevalence of those not on ART (red line), the 
reported number (green dots) the fitted number (green 
line) of people on ART  and all infected people (blue line); 
Figure 2E gives the incidence of HIV (red line), the rate at 
which people start ART (green line), the mortality of those 
on ART (black line) and of those not on ART (grey line). 
Figure 2F gives the cost of ART (green line)3 and the cost 
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of ART plus the cost of in-patient and out-patient care (red 
line).3  
 By 2015 the prevalence of HIV in adults is expected to 
be 2.5% (Figure 2D: blue line), the prevalence of HIV in 
adults not on ART (Figure 2D: red line) 1.8%, and the 
prevalence of adults on ART 0.63%. This means that about 
25% of all HIV positive adults will be receiving ART or 
about 50% of adults with a CD4+ cell count below 
350/μL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Top row: No ART. Second row: Current Programme. Third row: Accelerated Programme. Bottom row: Expanded Programme. 
Left: HIV prevalence. Blue: Data (with 95% confidence limits) and fitted line. Red: not on ART. Green: Data for those on ART and fitted 
line. Middle: HIV incidence. Red: Incidence of HIV. Green: incidence of treatment. Black: mortality not on ART. Grey: mortality on ART. 
Right: Cost. Green: ART. Red: Green plus hospitalization. Brown: Red plus cost of testing.  
 
Accelerated Programme 
The Accelerated Programme assumes that the number of 
people on treatment will be doubled by the end of 2015. 
(Figure 2G). This will require a massive campaign of 
testing and treatment with the associated logistical 
problems.  
 By 2015 the incidence will have fallen further from 
2.4% p.a. without ART to 1.8% per annum under the 
Accelerated Programme (Figure 2E: red line). The rate at 
which new people start ART will peak at 0.09% per 
annum in 2014 (Figure 2E: green line) but will fall after 
that. AIDS related deaths among adults will have fallen 
from about 0.2% p.a. without ART to 0.1% per annum 
under the Accelerated Programme (Figure 2E: black line). 
Without ART about 107 thousand people would have died 
by 2015; the provision of ART has reduced this to 71 
thousand saving 36 thousand lives. People will continue to 
die on ART (Figure 2E: grey line) but mainly from natural 
causes other than HIV. 
 Both the Current Programme and the Accelerated 
Programme have saved and will continue to save many 
lives but their impact on incidence and prevalence is much 
less; providing ART relatively late in the course of 
infection keeps people alive but only after they have 
infected several other people. There will also be a small 
but significant cost saving of about US$32M out of a total 
cost of up to 2015 of about US$547M.  The total cost 
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includes care and support, (Figure 2F: green line) and in-
patient and out-patient care (Figure 2F: difference between 
red and green lines). 
Expanded Programme 
The impact of the Accelerated Programme will be greater 
on mortality than on incidence or prevalence and the 
savings that accrue encourage one to consider the impact 
of expanding the programme further. If the Angolan 
government chooses to adopt the 2013 guidelines of the 
World Health Organization15 about 90% of all HIV-
positive people will be eligible for treatment as soon as 
they are found to be HIV-positive.16 The current (2013) 
guidelines of the International AIDS Society17 and the 
Department of Health and Human Services (DHHS)18 both 
recommend treatment for those infected with HIV without 
regard to their CD4+ cell count on the grounds that this is 
in the best interests of the individuals concerned and has 
the added benefit of reducing the likelihood that they will 
infect their partners.  
 We therefore consider what would happen under a 
policy of universal access in which 90% of all adults, not 
on ART, are tested each year and 90% of those that test 
positive are started on ART starting in 2015 and reaching 
full coverage by 2020. 
 Universal access to early treatment should eliminate 
HIV transmission (Figure 2J and Figure 2K: red lines) and 
AIDS related deaths by 2022 (Figure 2K: black line) but 
there will still be a very large number of HIV positive 
people on ART (Figure 2J: green line) who will have to be 
maintained on treatment for the rest of their lives. The rate 
at which people need to be started on treatment will 
increase to about ten times the present rate (Figure 2K: 
green line) in 2015 but after that will fall rapidly as 
transmission and the generation of new cases fell. The 
costs will begin to fall (Figure 2L: red and brown lines) as 
the prevalence of infection falls. There will be an initial 
increase in costs as the backlog of untreated patients is 
taken up. The cumulative costs to 2025 would not 
increase. Angola currently spends about US$215 per 
capita on health so that a policy of early treatment will 
only increase overall costs by about 2% of total spending 
on health up to 2025 but after that there would be 
considerable cost savings.  
PMTCT 
Bringing it all together 
Figure 3 is a direct comparison of what would have 
happened under the No ART counterfactual, what has 
happened under the Current Programme, what should 
happen under the Accelerated Programme, and what could 
happen under the Expanded Programme with universal 
access and early treatment following the 2013 WHO 
guidelines.  
 The Current Programme has already averted many 
new infections and saved many lives, and will continue to 
save, both lives (Figure 3A and B) and money (Figure 3C 
and D) but the epidemic will continue indefinitely.  
 The Expanded Programme will incur a small increase 
in costs as treatment is expanded (red and green lines 
(Figure 3C and D) but will save many more lives (Figure 
3A and B) and, in the long run, save more money (Figure 
3C and D), eliminate HIV and bring an end to AIDS 
related deaths (Figure 3A and B).  
Discussion 
Angola has a relatively small epidemic of HIV compared 
to other countries in southern Africa. The Angolan 
government has been successful in the extent to which it 
has made ART therapy available in the public sector. 
Currently, an estimated 42 thousand people are being kept 
alive on ART without increasing the cost. It is clear that 
expanding access will save more lives and, in the long run, 
will save money and eliminate HIV. 
The Angolan Government is now committed to an 
Accelerated Programme of action which will double the 
number of people on ART by the end of 2015 but many 
logistical problems will have to be overcome. Two critical 
issues are drug supply and adherence. A regular and 
reliable supply of drugs must be assured. Stock-outs will 
create anger and mistrust among infected people and poor 
adherence, for any reason, will lead to viral rebound, 
treatment failure, on-going transmission and drug 
resistance. These two considerations must be at the 
forefront of plans to effectively control and eventually 
eliminate HIV. Given the shortage of trained clinicians the 
programme will have to depend heavily on community 
mobilization and the training and support of a cadre of 
community health workers. However this help to facilitate 
community involvement, empower local people and 
especially women, create jobs and stimulate local 
economies.  
 The Accelerated Programme will provide a sound 
basis for further expansion of treatment as described in the 
Expanded Programme. With currently available 
interventions universal access to early treatment is the only 
way to eliminate HIV in Angola and all HIV-positive 
people will die of AIDS related conditions if the do not 
start ART and starting ART as soon as possible after sero-
conversion is in the best interests of the individual person. 
Other methods of support and control can and should play 
an important supporting role.16 To achieve high levels of 
compliance it will be necessary to deal with problems of 
stigma and discrimination and to ensure that there is strong 
community involvement and support for people living with 
HIV.  
While this paper focuses on treatment, continued scale-up 
of prevention interventions are critical to the HIV 
response. Condoms are highly effective if used properly 
and should be readily available to all that need them. 
Reducing the number of sexual partners and better control 
of other sexually transmitted infections are important in 
themselves and will contribute further to the control of 
HIV. Other prevention packages designed for key 
populations also need to be in place and can make an 
important contribution to stopping the epidemic of HIV; 
universal access to early treatment provides an ideal entry 
point for each of them. Finally, by developing programmes 
that are firmly based in local communities it will be 
possible to provide training and education while 
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employing community outreach workers thereby creating 
jobs and stimulating local economies and ensuring 
sustainability.  It is still important to confirm the 
validity or otherwise of these results and to improve the 
model predictions. Here we have used the reported 
coverage of ART but this has never been directly 
measured. To do so a sample of women who test positive 
for HIV each year should be tested for the presence of 
anti-retroviral drugs, their viral loads should be measured 
and an incidence assay should be used to estimate 
incidence. We have assumed a cost of US$250 per year for 
care and support of those infected with HIV. The results 
are sensitive to this assumption but this level of cost could 
be achieved if there is effective community support and 
mobilization. If this money were used to train and employ 
community health workers it would create jobs and 
provide an important stimulus to local economies in the 
poorest communities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Left column annual rates; right column cumulative numbers. A & B: HIV incidence. C & D: AIDS deaths. E & 
F: Cost; G & H: HIV-positive births. Blue lines: No ART counterfactual. Brown line: Current Programme. Red line: 
Accelerated Programme. Green: Expanded Programme. 
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 The Department of Health in Angola has already 
adopted the new WHO guidelines, with an opt-out 
approach for those with a CD4 cell count below 500 
cells/µL. However, many facilities in Angola lack working 
CD4 machines. Since an estimated 90% of all HIV 
positive people will be eligible for immediate treatment 
according to the new WHO guidelines, it would be 
advisable to abandon the use of CD4+ cell counts but to 
make viral load testing more widely available as a way of 
assessing the impact of the programme and of monitoring 
compliance. Under the Expanded Programme the rate at 
which people are started on ART will have to be increased 
by about ten times, but only for about two years as the 
intervention will rapidly reduce the incidence of new 
infections (Figure 2I). While this will require considerable 
organization it will only incur a marginal increase in costs 
for about five years and within a few years the savings in 
lives and money will be substantial. 
 What is needed now is informed leadership, an 
Accelerated Programme of ART provision, and if this can 
be successfully completed a further Expanded Programme 
of universal testing and immediate access to treatment, 
combined with good operational research, while 
monitoring the impact and implementation of the new 
programme. The sooner that this is started the more lives 
and money that will be saved. Angola has the wherewithal 
to stop the epidemic; all that is needed is the commitment 
and determination to achieve an AIDS Free Generation.
Table 5. Measured prevalence of HIV (%) among women attending ante-natal clinics at different facilities in the various 
provinces of Angola. Vertical grey lines indicate years in which no data were collected. Propn. gives the population in each 
province as a proportion of the total population. 
No. Facilities Province Propn. 1992 1993 1994 1995 1996 1998 1999 2001 2002 2004 2005 2007 2009 2011 2012
  1 Maternidade do Caxito   Bengo 13.9          1.20 1.81 4.51 3.25 3.00  
  2 Benguela   Benguela          0.60 2.80 2.41 5.00 4.60  
  3 Maternidade do Lobito   Benguela 
7.6 
         0.60 2.61 3.60 3.80 3.80  
  4 H.Prov.Kuito (Maternidade)   Bie 4.5          0.60 0.81 1.60 3.20 5.80  
  5 C.M.I. Cabinda   Cabinda          3.00 3.22 2.80 3.00 2.60 5.60  
  6 Cabinda Province  Cabinda 2.8 6.00 7.00 7.00 5.00 8.00  8.00         
  7 Cacongo  Cabinda             3.42 0.94 1.00 1.00 
  8 Cahama  Cunene             2.40 2.60 3.60 3.6 
  9 H.Prov.Ondjiva(Maternidade)  Cunene 2.6         12.00 8.80 10.62 9.40 7.40 8.22  
10 Ombanja   Cunene             4.00 3.17 2.41 2.41 
11 Maternidade do Huambo   Huambo 6.5          2.40 1.81 3.60 4.20 3.40  
12 Matala  Huila            1.20 1.60 2.40 2.4 
13 Maternidade do Lubango   Huila 
8.0 
       4.00 1.00 2.60 4.03 3.01 2.80 4.39  
14 H.Prov.Menongue(Maternidade)  Kuando Kubango 1.6          4.03 3.00 4.80 4.20 5.59  
15 H.Central Ndalatando(Dr.A.A.Neto)   Kwanza Norte 1.5          1.00 1.20 1.60 1.00 2.00  
16 Centro Policlínico da Cidade (Sumbe)  Kwanza Sul          0.80 1.40 1.40 1.00 1.40  
17 Gabela Kwanza Sul 
5.4 
           2.60 1.00 0.40 0.4 
18 C. S. Viana (Ana Paula)   Luanda           2.20 2.81 1.80 3.00 4.78  
19 C.S Ilha Luanda             2.86 3.40 5.20  
20 C.S Samba  Luanda             3.80 4.60 5.40  
21 C.S. Asa Branca   Luanda          4.00 2.00 1.81 0.60 1.60 2.40  
22 C.S. Cacuaco  Luanda 22.2          1.80 1.21 1.80 2.20 2.60  
23 C.S. Hoji ya Henda   Luanda          2.00 3.80 4.41 1.80 3.20 1.41  
24 H. Kilamba Kiaxi   Luanda          3.00 3.86 2.84 4.00 3.00 2.59  
25 Luanda   Luanda     1.00  3.00 3.00 8.00        
26 Lucrecia Paim  Luanda           4.40 2.00     
27 Maternidade Ngangula   Luanda           4.36 3.82  4.80 2.81  
28 H. Dundo (Maternidade)   Luanda Norte          3.40 3.41 6.60 5.60 6.36  
29 Nzage-Cambulo   Luanda Norte 
3.1 
           3.60 2.87 3.80 3.8 
30 C.M.I. Saurimo   Lunda Sul         1.00 3.42 3.60 4.60 2.80 4.00  
31 Muconda  Lunda Sul 
1.5 
           0.75 2.23 2.99 2.99
32 C.S. Ritondo   Malange 2.9          1.40 1.80 1.80 0.80 1.60  
33 C.M.I. Luena  Moxico          2.61 2.00 3.20 3.00 3.01  
34 Luau   Moxico 
2.2 
           2.40 0.60 2.99 2.99
35 H. Mat.Infantil do Namibe  Namibe 1.5          2.00 3.60 2.12 3.70 4.01  
36 Maternidade de Uige  Uige          4.90 1.00 0.60 1.00   
37 Negage   Uige 
4.2 
           1.80 1.00 0.60 0.6 
38 C.S 1º de Maio Zaire Zaire          2.20 2.10 3.60 1.60 1.41  
39 H.P Zaire  Zaire 
1.6 
           2.31 0.80 0.60  
 
Appendix 1 
HIV prevalence data for women attending ante-natal clinics 
are given in Table 5. Because the data are sparse we 
consider each data set individually. Full details of the 
analysis are available from the author on request. We first 
consider the timing of the epidemics in the different 
provinces. The only data sets in Table 5 for which we can 
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identify the initial rise in the prevalence of HIV, with 
confidence, are those numbered 1, 2, 3, 6, 11, 25, 28, and 
30. Fitting logistic curves to these data shows that in all but 
two facilities the mean year at which the epidemic reached 
half of its asymptotic value (half-max.) was 2004.1 (Range: 
2002.6 to 2005.2; 95% confidence interval 2003.0 to 
2005.2). There are two outliers: data set No. 6 from 
Cabinda and data set No. 25 from Luanda.  
 The epidemic of HIV in Cabinda appears to have 
reached half-max. in 1989.8, 14 years before the other 
provinces in Angola. The enclave of Cabinda is separated 
from the rest of Angola by a strip of territory belonging to 
the Democratic Republic of the Congo and it is likely that 
the epidemic started in Cabinda earlier than in the rest of 
Angola. A separate analysis is therefore needed for Cabinda 
and since Cabinda only makes up 1.8% of the total 
population, we exclude Cabinda from this analysis. 
 There are 10 data sets for Luanda but in only one of 
them, No. 25 in Table 5, can we establish the timing of the 
initial rise of the epidemic. This data set only contains four 
points and they suggest that the epidemic in Luanda 
reached half-max. in 1999, five years before the rest of the 
data sets. However this data set is in conflict with the other 
nine for Luanda as it suggests an asymptotic prevalence of 
8.8% while the other nine suggest an asymptotic prevalence 
of 4.2% (95% CI: 2.8% to 5.6%). Since this data set 
contradicts the other nine data sets for Luanda as regards 
the asymptote and the other six data sets for the country as 
regards timing we exclude it from further analysis.* For 
data sets 1, 2, 3, 11, 28, and 30 in Table 5 we use the fitted 
values to determine the timing; for the remaining data sets, 
for which the timing cannot be determined, we use the 
average value estimated from these data sets and set half-
maximum. to 2004.1. This gives the epidemic trend used in 
the analysis (Figure 2). 
Appendix 2 
Analysing the data for Angola raises an important question. 
The initial rate of increase of the epidemic, from the best fit 
model has a doubling time of just less than one year which 
is about the same as it is in South Africa by way of 
comparison. However, the steady state prevalence in South 
Africa is about 15% and in Angola it is only 2.5%, about 
six times less. This suggests that only about one-sixth as 
many people (expressed as a proportion) are at risk of HIV 
in Angola as they are in South Africa. There are two 
standard ways of dealing with the problem of heterogeneity 
in the literature. The first assumes that there are two groups, 
one at a fixed risk and the other at no risk, the size of the 
risk group is then adjusted to match the observed peak 
prevalence. The second assumes that since those at high 
risk are likely to get infected earlier, the average population 
risk declines as the prevalence increases and the present 
author has generally assumed that transmission declines 
exponentially with prevalence. These two assumptions 
correspond to either a step-function distribution of risk or a 
                                                          
*  Consultation with the Angolan Ministry of Health, the Instituto 
Nacional de Luta contra SIDA (INLS) and WHO confirmed this 
decision since most data in Angola were collected after 2004 and the 
early data from Luanda may include data from other provinces. 
risk that declines exponentially with prevalence. In the case 
of Angola the prevalence saturates at a very low level and, 
if we assume that transmission declines exponentially with 
prevalence, the model becomes unstable. We therefore 
assume that the decline in transmission with prevalence 
follows a Weibull survival curve with a variable parameter 
so that 
 ( ) ( )e kPP αλ −=  
where λ is the transmission parameter and P is the 
prevalence of HIV. The parameter α determines the level at 
which the prevalence peaks and the parameter k determines 
the shape of the function. With k =1 the function is 
exponential; with k = ∞ the function is a step function. The 
value of k that gives the best fit to the data is 2.25. 
Appendix 3 
The World Health Organization guidelines15 of 2013 advise 
HIV-positive people to start ART if their CD4+ cell count 
is less than 500/μL, if they have TB or Hepatitis B, if they 
are pregnant, under the age of five years, or in a sero-
discordant relationship. Data on the distribution of CD4+ 
cell counts in HIV-negative people19 suggest that about 
80% of all those currently infected with HIV in South 
Africa and not on ART will have a CD4+ cell count below 
500/μL. If we include the other groups of people that 
should start treatment irrespective of their CD4+ cell count, 
then about 90% of all HIV positive people are currently 
eligible for ART.4 
 If there is a need to triage people in order to treat those 
at greatest risk first, the sensible way to do this would be on 
the basis of their viral load. Individual CD4+ cell counts 
can vary by an order of magnitude within populations,19 the 
mean CD4+ cell count can vary by a factor of two between 
populations,19 and survival is independent of the initial 
CD4+ cell count.19,20 CD4+ cell counts therefore have very 
little prognostic value except in that unfortunate 
circumstance when the count is very low by which time an 
infected person is likely to be in WHO clinical stages III or 
IV and in need of immediate treatment anyway. 
Considerable savings in time, human resources and money 
could be had by abandoning the use of CD4+ cell counts to 
decide on when to start ART. People with a high viral load, 
on the other hand, have a reduced life expectancy21 and are 
more infectious than those with a low viral load.22 If the 
availability of anti-retroviral drugs is limited it would 
therefore have the greatest benefit for individual patients 
and have the greatest impact on transmission if preference 
was given to people with high viral loads.23 
Appendix 4 
The current cost of drugs in Angola is given in Table 6. The 
cost of ART drugs has dropped from US$10,000 p.a. in the 
year 2000 and has fallen to about US$100 p.a. in South 
Africa. The drugs costs in Table 6 are likely to fall 
considerably in the near future. For the purposes of this 
study we therefore include only the cost of first line drugs. 
Since, under option B+ for pregnant women by far the 
greatest costs will be incurred during the life-time spent on 
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ART following the birth of the child. We therefore use the 
annual cost of first line drugs for all women who start on 
option B+ 
Table 6. Annual cost of anti-retroviral drugs, support which 
includes drug delivery and monitoring, and upstream costs 
(US$). 
 Drugs Support Upstream  Total 
First line  354 357 284 995 
Second line 1059 350 564 1973 
Children 163 300 185 648 
PMTCT  764 350 446 1560 
 
 We combine ‘support’ and ‘upstream’ costs under the 
heading ‘Community care and support’ in Table 1. 
 We do not have estimates of the average number 
inpatient or outpatient days or primary health care visits for 
HIV-positive people who are or are not on ART and we use 
corresponding estimates for South Africa.  
 We estimate the annual costs per person reached or 
tested to be: community mobilization US$3.38; condom 
distribution and promotion US$0.18; testing and 
counselling US$14.87 for a total of US$18.43. In Table 1 
we allocate US$20 for counselling and testing per person 
tested. 
 We estimate policy and program support expressed as a 
percentage over direct costs to be: creating an enabling 
environment 0.8%; program management 2.6%; research 
0.7%; monitoring and evaluation 1.0%; strategic 
communication 2.3%; logistics 1.2% for a total of 8.6%. 
Since these costs only add an additional 8.6% to the total 
costs and given the great uncertainty in the cost estimates 
we do not include these costs in this calculation. 
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